LOS ANGELES, April 14 (Reuters) - Roche Holding AG, which last month acquired Genentech Inc, said on Tuesday that Arthur Levinson, the biotech company's chief executive, would stay on as chair of a new Genentech board.
The Swiss company also said Levinson would steer integration of the two companies, serve as a scientific adviser and be nominated to the Roche board.
Roche said Susan Desmond-Hellmann, president of product development at Genentech, will hand over her current responsibilities by mid-year, after which she will also act as an adviser to the company and join the external scientific advisory board.
The company said Richard Scheller, executive vice president of Genentech research, will lead an independent research and development group within Roche, which will report directly to Chief Executive Severin Schwan.
Roche also said that William Burns, CEO of the Roche pharmaceutical group, will retire Jan. 1, and will also be nominated to the company's board.
(Reporting by Deena Beasley, editing by Matthew Lewis) Keywords: ROCHE GENENTECH/ (deena.beasley@thomsonreuters.com; + 1 213-955-6746; Reuters Messaging: deena.beasley.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
The Swiss company also said Levinson would steer integration of the two companies, serve as a scientific adviser and be nominated to the Roche board.
Roche said Susan Desmond-Hellmann, president of product development at Genentech, will hand over her current responsibilities by mid-year, after which she will also act as an adviser to the company and join the external scientific advisory board.
The company said Richard Scheller, executive vice president of Genentech research, will lead an independent research and development group within Roche, which will report directly to Chief Executive Severin Schwan.
Roche also said that William Burns, CEO of the Roche pharmaceutical group, will retire Jan. 1, and will also be nominated to the company's board.
(Reporting by Deena Beasley, editing by Matthew Lewis) Keywords: ROCHE GENENTECH/ (deena.beasley@thomsonreuters.com; + 1 213-955-6746; Reuters Messaging: deena.beasley.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.